A Randomized, Parallel Group, Single-Blind, Phase 2 Study to Evaluate the immune response of two classes of SARS-CoV-2 Vaccines (COVID-19) employed as Second Boost in Patients under current Rituximab Therapy and no humoral response after standard mRNA vaccination
Latest Information Update: 11 Sep 2023
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 08 Sep 2023 Planned number of patients changed from 60 to 68.
- 17 Aug 2022 Results of open label extension published in the Annals of the Rheumatic Diseases
- 13 Jan 2022 Primary endpoint (Difference in SARS-CoV-2 antibody seroconversion rate by week 4 after vaccination boost at baseline between 3rd mRNA SARS-CoV-2 (Biontech/Pfizer or Moderna) and vector SARS-CoV-2 vaccine (AstraZeneca) ) has not been met according to the results published in the Annals of the Rheumatic Diseases